Purpose of Review The purpose of this review was to summarize and reflect on advances over the past decade in human genetic and metabolomic discovery with particular focus on their contributions to type 2 diabetes (T2D) risk prediction. Recent Findings In the past 10 years, a combination of advances in genotyping efficiency, metabolomic profiling, bioinformatics approaches, and international collaboration have moved T2D genetics and metabolomics from a state of frustration to an abundance of new knowledge. Summary Efforts to control and prevent T2D have failed to stop this global epidemic. New approaches are needed, and although neither genetic nor metabolomic profiling yet have a clear clinical role, the rapid pace of accumulating knowledge offers the possibility for "multi-omic" prediction to improve health.
Introduction
The prevalence of type 2 diabetes (T2D) continues to increase worldwide, despite our efforts to treat and prevent it. New approaches are needed to control T2D and its fearsome complications. In the last decade, the combination of stunning advances in genotyping and sequencing efficiency, metabolomic profiling, bioinformatics approaches, and international collaboration has moved T2D genetics from a state of uncertainty to an abundance of new and reproducible findings. There has been great hope that understanding the genetic and biological basis of disease would quickly yield improved diagnoses and new therapeutics [1] . However, the path from discovery to clinical translation has not been straightforward, highlighting the complexity of genetic architecture in common diseases. Several recent review articles have primarily focused on follow-up translation of new genetic discoveries in several key directions. These directions include experiments defining the causal variant at an association locus, determining the variant's ultimate molecular and physiological function, and attempt to turn this new biology into drug target discovery [2] [3] [4] . In the present review, we summarize current progress in T2D genetic discovery, then turn to new discoveries of metabolomics species associated with T2D, and finally synthesize genetic and metabolomic ("multi-omic") applications to translate discovery for prediction of T2D risk and complications.
identified, most through genome-wide association studies (GWAS), explained further below. These discoveries provide considerable insight into the pathogenesis of the disease and its related metabolic traits like fasting glucose and insulin.
Pre-GWAS Genetics
Analysis of genetic markers in families using linkage analysis was successful for identifying genes underlying monogenic forms diabetes, such as maturity-onset diabetes of young (MODY) [6, 7] and neonatal diabetes [8] [9] [10] . However, linkage analysis did not lead to reproducible results for T2D, most likely due to the polygenic nature of the disease.
Shifting the focus from families to large populations of individuals, genetic association studies subsequently became a popular tool for T2D gene discovery. These studies compare the frequency of a genetic polymorphisms in large populations of cases to that of controls with the goal of highlighting genetic variants that differ in frequency between the two groups and thus are associated with disease risk. Initially, the genetic association approach was applied to selected chromosomal regions and genes, chosen based on prior knowledge of biology implicating the regions/genes in causing T2D. This approach, as was the case for linkage analysis, did not yield reproducible results, with the exception of three discoveries: the p.Pro12Ala polymorphism in the peroxisome proliferatoractivated receptor gamma 2 (encoded by PPARG) in 2000 [11] , the p.Glu23Lys polymorphism in the islet ATPdependent potassium channel Kir6.2 (encoded by KCNJ11) in 2003 [12] , and the TCF7L2 locus in 2006, which was discovered in an area of suggestive linkage [13] . Thus, prior to early 2006, only three genetic variants were reliably associated with T2D.
GWAS
The introduction of GWAS dramatically changed the landscape of the field. GWAS involve a genome-wide set of common genetic variants tested in large sets of cases and controls for an association with a trait such as T2D. In contrast to candidate gene studies, GWAS offer an "hypothesis-free" approach and rapidly led to the discovery of dozens of new genetic loci associated with T2D [14••] . Including multiethnic populations in GWAS, meta-analyzing multiple GWAS to increase sample size, and performing imputation against reference sequences, all further expanded the number of loci to just over 100 [15•, 16, 17••, 18, 19] . The variants identified through GWAS thus far individually confer small increased risks of T2D (odds ratios generally less than 1.3) and, combined, they explain about an estimated 10-20% of the familial aggregation of the disease [15•, 17••, 20, 21] .
Simultaneously, GWAS were performed in additional metabolic traits related to T2D. Results from GWAS of glycemic traits were of particular interest for elucidating the mechanistic pathways underlying the associations of variants with T2D risk and showed that the majority of the initial T2D loci discoveries were related to β cell function as opposed to insulin resistance (IR) [22, 23] . T2D loci, predominantly identified through GWAS, are shown in Fig. 1 , highlighting those loci that are also significantly associated with glycemic traits.
Exome Chip and Next-Generation Sequencing
The introduction of massive parallel sequencing technologies facilitated high-throughput sequencing of individuals with and without T2D. Additionally, exome arrays, designed to capture low-frequency (minor allele frequency [MAF] < 5%, but > 0.5%) variation in the genome, provided a cost-effective intermediate option between GWAS and sequencing. Despite large-scale efforts involving tens of thousands of individuals, few new T2D loci have yet to be identified through exome array, exome sequencing, or whole-genome sequencing. For example, in the largest exome sequencing study to date with 13,000 individuals, only one variant reached genome-wide significance (PAX4 p.Arg192His with odds ratio 1.79), which resides in a locus that had previously been identified through GWAS, although the two signals were not in linkage disequilibrium (r 2 < 0.05) [24••] . PAX4 p.Arg192His was seen almost exclusively in East Asians, where it was common (MAF 10%) [24••] . In the new loci identified through exome chip and sequencing technologies, which included CCND2, PAM, COBLL1, MACF1, and MTMR3/ASCC2 [24••, 25, 26, 27 •], the majority of the T2D-assocatied variants were likewise common (MAF > 5%).
Genetic Architecture of T2D
These T2D genetic studies highlight two key take-away messages related to the genetic architecture of the disease and its implications for T2D risk prediction. The first take-away message relates to a controversial question that has long plagued the field of T2D genetics and other complex traits: does the genetic architecture of T2D involve mainly common variants with small effects (common disease/common variant hypothesis) or mostly rare variants (MAF < 0.5%) with large effects [28] ? Results from the abovementioned studies, particularly the analysis of 13,000 exomes [24••] , suggested that lowfrequency and rare variants contribute much less to T2D heritability than common variants, supporting the common disease/common variant hypothesis. Furthermore, the vast majority of variants that have been identified through sequencing have small effects on disease risk, with very few increasing risk of T2D by more than 2-fold. The exceptions of genetic variants conferring more sizeable T2D risk have been found in specific population groups (such as in p.Arg694Ter TBC1D4 in Greenland with odds ratio~10 [29] or HNF1A p.Glu508Lys in Mexico with odds ratio~5 [30] ), and in each case, the genetic variants were particular to these populations. While T2D thus appears to be a predominantly common variant polygenic disorder, the impact of rare genetic variation on T2D risk has not yet been fully evaluated since recent sequencing studies have been under-powered, and exome array and imputation studies, which are more easily scalable to large sizes, are still unable to fully capture rare genetic variation throughout the genome.
Implications for Clinical Translation
The second take-away message relates to the challenge of uncovering genes causing T2D. Across all phenotypes, GWAS signals have pointed predominantly (over 80%) to non-coding regions of the genome, suggesting that their impact is likely due to gene regulation [31] . There have been examples of elegant functional work and follow-up studies elucidating biology related to T2D GWAS loci (e.g., MTNR1B and its role in circadian rhythm [32] [33] [34] [35] ); however, for the majority of loci, the mechanisms by which the T2D-associated chromosomal regions cause disease, including which genes are involved, remain unknown. As a result, it has been difficult to understand the biology underlying GWAS loci and translate findings into clinical care [36, 37] .
Nevertheless, there is reason to believe that GWAS discoveries may have clinical implications [37] . To begin with, the fact that T2D GWAS loci involve genes encoding targets for drugs used to treat T2D (e.g., PPARG for thiazolidinediones and KCNJ11/ABCC8 for sulfonylureas) suggests that these genetic regions may direct us to additional drug targets [2] , although it may require sifting through hundreds of possible genes within loci. Additionally, even without understanding mechanistic pathways or pinpointing causal variants/genes, GWAS findings can be used in aggregate for T2D risk prediction, as will be discussed in detail in the following section. The rapidly growing number of identified T2D loci explains an expanding proportion of T2D inherited risk, currently estimated to be up to 20% [17••, 21] . Increasing sample sizes of genetic association studies will likely enable discovery of hundreds of additional loci. While such additional loci are expected to have decreasing magnitudes of effect sizes [15•, 24••] , in aggregate, they may still facilitate improved T2D risk prediction.
Genetics for Prediction of T2D and T2D Comorbidities

Prediction of Future T2D
In addition to unveiling new biological mechanisms in glucose metabolism, regulation and perturbation, and T2D susceptibility, T2D genetics can also be applied to de novo populations to predict future T2D. There has been great interest as to whether such prediction could be clinically relevant. T2D-related genetic variants discovered through largescale GWAS have mostly modest effects individually, as noted above; however, they can be combined together to form a genetic risk score (GRS). Index SNPs of reported T2D-related loci are selected to construct the GRS. The number of risk alleles is counted for each individual across all SNPs. GRSs can be unweighted (i.e., each risk allele has an equal weight in the score) or weighted by reported effect sizes. GRSs predict future T2D across ethnic groups and also across age groups (youth as well as middle age) [38-40, 41•] . The efficacy of genetic prediction of T2D may be tested through the use of the receiver operator characteristics curves; the area under the curve (AUC) estimates the probability that the model correctly discriminates individuals at higher risk of T2D from those at lower risk; for instance, the probability that among a pair of randomly selected individuals, only one of whom will develop T2D, the model will correctly identify that at-risk individual. The most recent study evaluating GRS for incident T2D prediction was conducted in two cohorts, one of only white participants with mean baseline age of 36 years (Framingham Offspring Study) and a second of white and black Americans selected to be younger with baseline ages 18 to 30 years (Coronary Artery Risk Development in Young Adults) [41•] . The authors tested a genotype score composed of 62 T2D associated variants and found that the GRS added little to the clinical prediction (including BMI, systolic blood pressure, fasting plasma glucose, cholesterol levels, and parental history of T2D) in both populations, although it did significantly improve the AUC in the cohort of only white Americans [41•] . These results were consistent with two similar earlier studies in individuals of European descent, which used up to 18 T2D-associated variants for the genetic risk scores [38, 42] .
Despite the large number of T2D-related variants discovered to date, the application of GRS for the purpose of T2D prediction and risk stratification of populations faces several challenges. First, the common genetic variants used in the aforementioned models explained less than 20% of variance estimated on the liability scale [16] , which may explain in part why GRSs have had moderate predictive ability for incident T2D [41•] . Second, although GRSs predict incident T2D independently of commonly measured clinical risk factors (e.g., fasting glucose, BMI, and family history), common genetic variants add little to the predictive performance of models that already include these variables [41•] . This could be partly explained by the rather strong predictive ability of measured clinical variables which have AUCs greater than 80%, and so additional predictors are less likely to improve model prediction substantially. Third, the majority of T2D variants have been identified in European populations or trans-ancestry meta-analyses that are still predominantly European [17••] . While many loci associated with T2D and related glycemic traits are transferrable across different ancestries [17••, 18, 19, 43-45] , sample sizes of these non-European GWASs are often smaller than European GWASs, and so discovery of variants in these populations has lagged behind those in European populations [19, 27•, 29, 43, 46-48] . A GRS composed of T2D-related variants that are common in people of European descent, but of lower frequency in other ancestries, may not evenly predict incident T2D in diverse populations even if genetic effects were consistent across ancestries.
The third issue of transferability of GRS to non-European populations may be addressed by including T2D-related variants that are unique to specific populations to further improve prediction of ancestry-specific GRSs. Additionally, ancestryspecific effect estimates derived from GWAS can be used to weight the GRS. However, the smaller sample sizes of these ancestral groups, compared to Europeans, still limits how well effect sizes are estimated, and so ancestry-specific weights may not necessarily improve their predictive ability. Another strategy would be to reassign the index variant in Europeans to another variant within the same locus that has a stronger association in the other ancestry; however, again, the smaller sample sizes of non-European ancestries may result in "chance" reassignments and again poorly estimated weights.
Therefore, despite great interest from researchers and the emergence of commercial products to use GRSs for T2D risk prediction, published approaches using up to 62 T2D variants have not shown clinical utility over standard risk factors, and there is valid concern about transferability of GRSs to nonEuropean populations. Nevertheless, the number of known genetic loci has already almost doubled beyond the 62 variants included in the most recent study and fine-mapping studies have uncovered multiple distinct signals and prioritized causal variants within some of T2D-related loci. Improving the characterization of genetic loci will allow for more robust modeling of genetic risk factors for T2D and potentially greater predictive power and clinical impact.
Relationship of T2D Genetics With T2D Comorbidities
In addition to their application to T2D prediction, polygenic risk scores composed of T2D-related variants may also serve as "genetic instruments" in Mendelian randomization (MR) analyses (see [49•, 50-52] for methodological details). Instrumentation in a MR approach evaluates the effect of a risk factor on an outcome using genetic variants as instrumental variables to investigate potential causal relationships. MR can therefore be used as a tool to strengthen causal inference, lending support for T2D as a clinical risk factor for disease susceptibility.
Observational epidemiologic studies have identified multiple disease conditions that tend to occur more frequently in patients with T2D compared those without T2D. These comorbidities include microvascular and macrovascular disease, obesity, hypertension, dyslipidemia, fatty liver disease, fractures, cancers, infections, hearing impairment, low testosterone levels in men, polycystic ovarian syndrome, obstructive sleep apnea, periodontal disease, mental health and psychological disorders, cognitive impairment, and dementia [53] . However, the extent to which these associations are attributed to confounding, reverse causation, shared risk factors, or genetic underpinnings is unclear. T2D GWAS variants, individually or as a group sharing a biological pathway, may have mediated effects through T2D on these other disease conditions, potentially illuminating underlying genetic relationships between T2D and comorbidities. For example, MR studies have shown that genetically increased T2D risk increases risk of coronary artery disease (CAD) [54, 55] , large artery-and small vessel-stroke [56] , and arterial stiffness [57] and decreases estimated glomerular filtration rate [58] . MR approaches can also be used disentangle complex biological relationships connecting diseases. By using a genetic instrument composed of genetic variants that have been reported to be associated with fasting glucose but not T2D, it was shown that genetically driven hyperglycemia increases CAD risk separately from the risk conferred by T2D as a whole [59] . Using a similar approach, another MR study showed that genetically increased T2D risk independent of BMI is causally associated with higher femoral-neck bone mineral density [60] . Conversely, MR studies can provide evidence suggesting no or weak causal associations. Despite epidemiologic evidence for T2D as a risk factor for Alzheimer's disease and diminished cognitive ability [53] , genetically increased T2D risk has not been shown to be significantly associated with these outcomes in MR studies [61, 62] .
Genetic discovery continues to inform T2D GRSs that have the potential to more clearly elucidate the relationship between T2D and comorbidities than classical epidemiological studies where residual confounding can obscure or distort exposure-outcome relationships. Nevertheless, selecting only valid genetic instruments to enter the GRS remains a challenge in MR studies. Some T2D-related SNPs may be associated with the disease outcome in question through pathways that are independent of the intermediate phenotype, rendering those invalid instruments which may bias causal estimates. A clearer understanding of the biological function for every reported T2D-related genetic variant could improve the selection of valid instruments for MR analyses. Additionally, work in this area will benefit from deep phenotyping of large cohorts of patients. Biobanks linking genetic data to electronic health medical records containing diverse, hard-to-capture clinical outcomes offer an exciting opportunity to establish such cohorts with longitudinal follow-up.
Metabolomics Discoveries for T2D Risk
Complementary to genetic analysis, metabolomics offers physiological insight into disease through comprehensive profiling of small molecule metabolites in body fluids, cells, tissues, or whole organisms. It has emerged as an integrative tool of biological status as it allows measure of chemical phenotypes that are downstream of genomic, transcriptomic, and proteomic variability [63] . During the last decade, particular attention has been focused on metabolomics of IR and T2D given the natural connection of these conditions to dysfunctional body metabolism.
Researchers have taken both targeted and untargeted approaches to analyze metabolomics data. Targeted approaches focus on measurement of known metabolites in clusters with similar chemical structures based on stable isotope-labeled metabolites as internal standards (usually~300 metabolites can be detected). Non-targeted approaches are able to detect up to 10,000 independent spectral features, but only about one third of the detected peaks can be linked to a specific chemical structure [64••] . Table 1 summarizes published metabolomics discoveries for T2D.
Metabolite Associations With T2D and IR
One of the first insights in the field was the correlation between branched-chain amino acids (BCAA) and aromatic amino acids with IR reported around 50 years ago [78] . Since then, dozens of large prospective analyses using either targeted or untargeted metabolomics approaches have validated the association. For example, in a nested case-control study using samples from two large prospective cohorts, elevated plasma levels of BCAA and aromatic amino acids were associated with up to a 5-fold risk for future development of T2D [77] . In a recent systematic review and meta-analysis of prospective studies including up to 8000 individuals, T2D relative risk increased by~35% per SD increase in isoleucine, leucine, and valine. Similar effect sizes were reported for increased tyrosine (1.36 [1.19-1.55] ) and phenylalanine (1.26 [1.10-1.44]) [79] . Furthermore, a large cross-sectional study in women revealed that, in addition to BCAA, downstream BCAA metabolic products such as branched-chain ketoacids and carnitines were significantly elevated in both individuals with impaired fasting glucose and subjects with T2D compared to control subjects [80] . Other products of amino acids catabolism, such as 2-aminoadipic acid (2-AAA) or α-hydroxybutyrate, have been found to be strongly correlated with incident T2D [71, 72] .
The associations from these observational studies may not necessarily represent causal relationships. Interventional studies offer the opportunity to assess causal relationships between metabolites and T2D risk. For example, in individuals who underwent bariatric surgery, BCAA levels were significantly reduced after massive body weight reduction [81, 82] . In a post-hoc analysis of the Diabetes Prevention Program, a randomized clinical trial including~3000 high T2D risk individuals allocated to intensive lifestyle intervention, metformin, or placebo, researchers showed that betaine, serine, and methionine sulfoxide, but not BCAA, were associated with incident T2D in all study arms independent of confounders [83] . Other amino acid levels have been inversely associated with risk of IR or T2D. For example, lower glycine concentrations were associated with higher IR [73] and were able to predict T2D incidence in different studies [70•, 75, 84•, 85] . Glycine is an upstream precursor for glutathione synthesis [86] , and, as expected, lower levels of glutamine and glutamine-to-glutamate ratio were also associated with higher risk of incident T2D, even after adjustment for confounders like body mass index and BCAA [73, 74, 87, 88] .
Lipidomics of T2D
Lipidomics, a subset of metabolomics including lipid classes, has expanded the range of metabolites associated with T2D risk and shed light on IR and T2D physiopathology. For example, much attention has recently focused on acylcarnitines as predictive biomarkers for IR and T2D given that they are end-products of dysfunctional mitochondrial β-oxidation [89] . In a recent large prospective study evaluating the association between 30 different acylcarnitines species and T2D relative risk, long-chain acylcarnitines were significantly associated with future risk of T2D [67] . In line with these findings, a global mapping study of molecules, associated with β cell dysfunction and T2D progression using islets from mice and humans, found that N-acyl taurines and stearoylcarnitine (a longchain acylcarnitine) accumulated in β cells and led to an arrest of insulin synthesis via excessive β-oxidation and depletion of TCA cycle [90] . M a n y l i p i d c l a s s e s i n c l u d i n g g l y c e r o l i p i d s , sphingolipids, or glycerophospholipids have also emerged during the last few years as critical components linking obesity to IR or T2D. These molecules are likely to reflect liver or adipose tissue misbalances in certain biological conditions, thus providing future opportunities for therapeutic targets [91] . A lipidomic profiling from the Framingham Heart Study cohort revealed that triglycerols (TGs) that contain fatty acids of lower carbon number and double-bond content were associated with increased incident T2D risk [76] . Interestingly, an insulin sensitivity intervention such as metformin administration or exercise was able to decrease "detrimental" TGs [76] . Among sphingolipids, the best characterized species are ceramides due to their link with obesity, IR, and metabolic disorders [92, 93] . Extensive research has suggested that an increase in specific ceramide species, such as palmitoyl ceramide or C16:0 ceramide, can inhibit fatty acid β-oxidation and negatively regulate insulin signaling and energy expenditure in obese humans and mice [94, 95] . Bariatric surgery studies showed that plasma C16:0 ceramide drastically decreased after body weight loss and was positively correlated with a reduction in inflammatory cytokine involved in IR [96] .
Other lipid classes have also been associated with a favorable metabolic profile and lower T2D risk. For example, higher concentrations of glycerophospholipids, such as circulating lysophosphatidylcholines (LysoPC), were associated with reduced impaired glucose tolerance [68, 70•, 71, 97] . In a non-targeted metabolomics profiling study including 300 individuals who developed T2D and 300 matched controls, each SD increase in LysoPC(dm16:0) and PC(O-20:0/O-20:0) was associated with~80% lower T2D risk after 6 years of follow-up [68] . Finally, a novel class of endogenous lipids, branched fatty acid esters of hydroxyl fatty acids (FAHFAs), has been found to be highly expressed in adipose tissue and correlated with insulin sensitivity [98] . In addition, FAHFAs are reduced in adipose tissue and serum of individuals with IR and might enhance the effect of insulin on glucose uptake in adipocytes and augment glucose-stimulated GLP1 secretion and insulin secretion [98] .
Metabolomics for T2D Prediction
T2D develops over time in a progression from normal glucose homeostasis to impaired glucose homeostasis to overt diabetes. Therefore, metabolic imbalances that ultimately lead to T2D are likely to be present well before the emergence of manifest diabetes, making them an attractive predictive tool [77, 99, 100•] . Dozens of plasma metabolites have been associated with development of future T2D, as described above (and summarized in Table 1 ).
Metabolites in aggregate have been studied in multivariate models for prediction of incident T2D and have shown discrete improvement beyond traditional risk factors, although to varying degrees depending on the approach used. Studies focusing only on a select set of metabolites have found that they offer minimal improvement in AUC compared to other clinical predictors. For example in the Framingham Heart Study, the AUC was modestly improved when five amino acids were included in a prediction model compared to a model including age, BMI, and glucose (AUC RFs = 0.801 vs. AUC RFs + Met = 0.806) [77] . Similarly, when three amino acids and six lipid species were tested for prediction performance beyond traditional risk factors, there was again minimal gain (AUC RFs = 0.856 vs. AUC RFs + Met = 0.874) [83] .
In contrast, studies including larger numbers of metabolites in aggregate using modern statistical techniques such as principal component analyses (PCA), penalized regression models, or machine learning methods have found a greater ability of metabolites to improve T2D prediction. For example, in a study using PCA of a targeted metabolomics panel, T2D prediction improved by~5% when metabolites were added beyond conventional risk factors and lifestyle characteristics [70•] . Seven metabolites (five known and two unknown) also significantly predict the risk of T2D when added to a multi-marker score beyond established T2D risk factors including BMI, fasting glucose, and IR (AUC RFs = 0.76 vs. AUC RFs + Met = 0.82) [69] . In a different study aimed at investigating whether acylcarnitines improved T2D risk prediction, authors showed that the AUC improved to 0.89 in the full model compared with 0.73 in the conventional model after selecting relevant acylcarnitines using penalized regression models. [67] . Finally, in an effort to systematically investigate the predictive power of the entire metabolome in predicting the future risk of T2D using a machine learning approach in~150 non-diabetic individuals who progressed to overt T2D, it was reported that 16 metabolites, including hexoses, amino-acids, and unknown metabolites, predicted progression to T2D significantly better than the reference model based on clinical risk factors alone (AUC RFs = 0.68 vs. AUC RFs + Met = 0.77) [65] .
Taken together, current metabolomics work highlights the relevance of these metabolites to predict incident T2D risk beyond traditional risk factors; however, much more work is needed in the area of unknown metabolites and in reproducibility of measurements.
Integration of Metabolomics and Genomics
Genome-wide SNP data have been integrated with highthroughput metabolic profiling in multi-omic approaches to provide insights into how genetic variation influences metabolism and how such metabolic differences in plasma can help to identify relevant genes for complex diseases [101•] . To this end, several large-scale genomic and metabolomic studies have been published over the last few years not only expanding the spectrum of genetic variants mainly associated with inborn errors of metabolism [101•, 102•, 103] but also providing relevant information for complex diseases. For example, pooled data from four European cohorts, found that the CYP7A1 locus, encoding the rate-limiting enzyme in bile acid synthesis, was associated with lower concentrations of deoxycholic acid and higher T2D risk [66] . In this study, variants in or near SGPP1 (sphingosine-1-phosphate phosphatase 1), GCKR (glucokinase regulator), and FADS1/2 (fatty acid desaturases 1 and 2) were also associated with T2D-associated phospholipids and T2D risk.
In a subsequent MR analysis, using the PPM1K locus (which encodes a mitochondrial phosphatase that activates branched-chain α-ketoacid dehydrogenase (BCKD)) as a genetic instrument for leucine, isoleucine, and valine, BCAA was implicated in a causal role in the development of T2D [104] . However, given that BCKD has a range of substrates besides leucine, isoleucine, and valine, untangling which one or more of these substrates causes T2D is challenging. In addition, a recent MR analysis for BCAA suggested that higher BCAA levels do not have a causal effect on IR, but rather genetically raised IR drives higher circulating fasting BCAA levels [105] .
The MAGNETIC consortium, including up to 24,925 individuals with genetic and metabolomics data, identified eight novel loci associated with amino acid, pyruvate, and fatty acid levels [106] . Interestingly, using MR, the authors found that genetically elevated lipoprotein(a) alters metabolism of very low-density lipoprotein and triglycerides; since elevated lipoprotein(a) is also associated with coronary heart disease, this work elegantly demonstrated a causal pathway linking genetic risk to metabolic disease through an intermediate metabolomic pathway. Genetic variants have also been significantly associated with increased glycine (CPS1), serine (PHGDH), and betaine levels (SLC6A12 and BHMT) (all in the glycine biosynthesis pathway) [84•] . These genetic variants, interestingly, do not reside in known T2D loci, despite the fact that the glycine biosynthesis pathway has been associated with T2D in observational studies, as noted above [70•, 75, 85] . In a MR analysis using these variants as a genetic instrument to investigate whether glycine pathway has a causal role on T2D risk, results did not provide consistent evidence for a role of genetically altered glycine in T2D risk [71] . In these cases, inability to complete the causal pathways may be due to either weakly causal or non-causal metabolite associations with T2D; larger study sample sizes used in MR analysis would therefore likely aid in interpretation.
Finally, the combined impact of genetic and metabolite markers for multi-omic T2D prediction has recently begun to be assessed. Analysis by Walford et al. of 1622 non-diabetic participants from the FHS showed that a GRS composed of 62 T2D-increasing risk variants and nine metabolites, including three BCAA (isoleucine, leucine, valine, two ramified amino acids (tyrosine and phenylalanine) and two amino acids catabolism markers (2-AAA and glutamine/glutamate ratio)) significantly improved T2D prediction above traditional risk factors [107•] . As shown in Fig. 2 , a 62 variant GRS had an AUC of 64%; addition of metabolites increased the AUC to 82%, and the combination of genetics, metabolomics, and clinical factors had an AUC of 88% [107•] , meaning that using this final model as a prediction tool, we will be correct 88% of the time in identifying those individuals who eventually develop T2D. To place this in perspective, current cardiovascular disease risk prediction tools have AUCs in the range of 63-81% [108] . The results from Walford et al. suggest that metabolite and genetic traits also provide complementary information for the prediction of future T2D. In the future, multi-omic prediction needs to be tested in non-European populations and may benefit from additional dimensions of omic data such as expression profiling or proteomic screening.
Conclusion
As technological, computational, and collaborative advances continue to reveal the molecular foundations of T2D risk, new genetics and metabolomics knowledge will increasingly be tested for utility in clinical prediction of T2D and T2D complications in combined multi-omic prediction frameworks. We have learned that T2D is a highly polygenic, primarily common variant disorder. Germline genetic exposures are present at birth, predate post-natal environmental exposures, and remain easily identifiable throughout the lifespan, thus offering a reliable epidemiological exposure for disease prediction. Likewise, MR experiments support the notion that some metabolites may reflect subclinical disease states, early exposures, or upstream biology resulting in downstream disease risk. In multi-dimensional biological measurements, "omics" have given insights into biological pathways but have not yet been fully explored for combined genetic and metabolomic prediction. In the future, multi-omic prediction could also consider other levels of dimensionality including proteomic or expression profiling. Important challenges remain, however. Much of what is currently known has been derived from individuals of European ancestry. Trans-ethnic studies with larger samples of non-European ancestries are needed to improve prediction for all ancestry groups. More complex modeling, accounting for non-additivity of genetic or metabolomic effects, gene-gene interactions, gene-environment interactions, and gene-metabolite interactions, also have not been tested to improve the predictive performance of genetic or metabolomic profiling. Our efforts over the past decade to control and prevent T2D have failed to stop the epidemic, as rates of T2D continue to raise worldwide. New approaches are needed, and although neither genetic nor metabolomic profiling have yet demonstrated a clear clinical role or impact, the rapid pace of accumulating knowledge offers a promising path forward for omic prediction to improve health. In addition, increasingly deep phenotyping of large cohorts of patients in biobanks that link genetic data to electronic health medical records offers an opportunity to test these concepts in "real-world" patient data. As T2D detection and early treatment improves T2D outcomes [109] , it is imperative to continue to discover and test novel approaches for prediction and detection of T2D. Funding Information Research is supported by NIDDK U01 DK078616. JBM is also supported by K24 DK080140, and MSU is supported by NIDDK 1K23DK114551-01.
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